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Introduction 
 
 
  
Clinical Applications of a Combination Therapy using 8-Cl cAMP and 8-Cl Adenosine 
Erik Munoz, Andrea Saich, Andrew Cox and Dr. Yu-An (Peter) Chang 
Summary of Clinical Trials 
 
- The information toxicity and side effects of 8-Cl-cAMP is readily available 
• Patients at high dosages report decreased renal function and greater 
accumulation of drug [1] 
• Decreased renal function causes patients to also present with 
hypercalcemia and hepatotoxicity 
• The maximum dosage at which this drug can be administered without 
affecting renal function has been found to be 0.15 mg/kg/h, 3 days a 
week [1,2] 
- The cellular pathways effected by 8-Cl-cAMP are under investigation 
• Evidence has suggested the drug operates through p38 MAPK activation 
inducing apoptosis via extrinsic pathways [3] 
• These effects have already been paired synergistically with existing 
chemotherapies, including Paclitaxel [4] 
- Conversion of 8-Cl-Adenosine to 8-Cl-cAMP has been observed [5] 
• This ability to be interconverted illustrates that the effects of 8-Cl-cAMP 
can be supplemented with the less toxic prodrug, 8-Cl-Adenosine 
 
Conclusion 
 
 
Based on the evidence provided from 8-Cl-cAMP clinical trials, it is clear that this 
drug is a powerful tool that can be used to treat various types of cancer. This 
benefit comes at a price, however. The drug’s solubility means that plasma 
concentrations are harder to control. This is normally corrected by increasing the 
drug’s concentration, resulting in toxic side effects. This was seen in the clinical 
trials which brought about a decrease in research on this drug; many felt that the 
side effects were too costly for patients. However, adding the prodrug 8-Cl-
Adenosine may be able to minimize the side effects while maximizing the 
therapeutic effects. This is due to the convertibility of 8-Cl-Adenosine to 8-Cl-
cAMP. Adding 8-Cl-Adenosine would allow for the lowering of the 8-Cl-cAMP 
dosage as the body will produce this product as it converts 8-Cl-Adenosine. This 
also alleviates the need for time delayed delivery systems. This conversion takes 
time, meaning that the body will produce 8-Cl-cAMP at a constant rate, leveling 
the plasma concentration over longer periods of time. The combination of the 
conversion properties and the time it takes for the conversion to complete 
indicate that a combination of 8-Cl-cAMP and 8-Cl-Adenosine would provide the 
maximal therapeutic benefits with minimal side effects. These two drugs are thus 
prime targets for a combined clinical trial. 
 
 
Background 
 
 
 Both 8-Cl-Adenosine and 8-Cl- cAMP have been found to 
inhibit proliferation of cancerous cells. 8-Adenosine is 
under clinical phase I study at the M.D. Anderson Cancer 
Center under Dr. William Wierda for the treatment of 
chronic lymphocytic leukemia while 8-Cl-cAMP has 
advanced to clinical phase II studies. Within cells, 8-Cl-
Adenosine and 8-Cl-cAMP are inter-convertible and can 
serve as pro-drugs for each other. The mechanisms 
through which 8-Cl-cAMP demonstrated the anti-
proliferative effects have been studied and 
published.  Findings by Simona Lucchi et al, (2) indicate 
that 8-Cl-cAMP is more effective in inhibiting cancer cell 
growth than the other PKA I-selective analogs. In this 
specific investigation, the use of 8-Cl-cAMP was 
associated with cell apoptosis, whereas the use of PKA I-
selective analogs only inhibited cell growth.  During 
inhibition of the p-38 MAPK pathway, the pro-apoptotic 
effect of 8-Cl-cAMP was prevented. Further studies 
suggested that the 8-Cl-cAMP and PKA I-selective 
analogs acted through these mechanisms; cell growth 
arrest is induced in cells carrying the BRAF-1 oncogene 
in the presence of PKA I-selective analogs, and 8-Cl-
cAMP induced apoptosis through the p-38 MAPK 
pathway. These findings indicate that 8-Cl-cAMP indeed 
produces anti-cancer effects by slowing down cancer cell 
growth and inducing apoptosis for cancer cells. Thus 8-
Cl-Adenosine, as a pro-drug of 8-Cl-cAMP ensures a 
sustained concentration of 8-Cl-cAMP in the blood 
plasma. The synergistic effect of using 8-Cl-cAMP and 8-
Cl-Adenosine in multidrug combination therapy for cancer 
patients will maximize the clinical efficacy and duration of 
the anti-cancer effects. 
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 The Role of cAMP in Signal Transduction  
Dr. Cho-Chung from NIH first thought to use halogenated cAMP derivatives as competitive inhibitors of 
cAMP to slow down cancer cell mitosis (1).  Experimental results indicated that 8-Iodo cAMP did not 
have any biological activity, while 8-Bromo cAMP showed minimum inhibition, and 8-Chloro cAMP (8-Cl-
cAMP) provided significant anti-cancer activity. 
 
8-Cl cAMP was found to be a broad spectrum anti-cancer drug against many cancer cells in vitro - such 
as in leukemia, breast cancer, lung cancer, etc. This molecule helped to slow down cancer cell growth 
giving time for the cancer cells to respond to signals from surrounding normal cells. This gave white 
blood cells sufficient time to recognize and eliminate the cancerous cells. Additionally, some of the 
cancer cells were observed reverting back to normal cells morphologically.  
 
With its many positive results, 8-Cl cAMP entered Phase II clinical trials. However, the phosphate group 
on the 8-Cl cAMP made it very water soluble; consequently, it quickly flushed out of the patients’ body, as 
do hydrophilic vitamins such as Vitamin C. Peristaltic pumps were thus employed to pump the 8-Cl 
cAMP into patients’ veins continuously to maintain drug concentrations. Although 8-Cl-cAMP had very 
low human toxicity, high exposures to this drug resulted in side effects that prevented it from reaching 
Phase III clinical trials. 
 
Since Adenosine can be converted to cAMP in vivo through the human biological pathway naturally, 8-Cl 
cAMP therefore can also be converted from 8-Cl-Adenosine through the same biological pathway. This 
has been confirmed by many published studies. Thus 8 Cl-Adenosine can serve as a pro-drug for 8-Cl-
cAMP to provide a constant concentration of 8-Cl-cAMP in the cancer patient blood plasma. This can 
also reduce the dosage necessary for treatment. The combination therapy using 8-Cl cAMP and 8-Cl 
Adenosine (as a pro-drug of 8-Cl cAMP) will certainly provide the optimum clinical outcomes for cancer 
patients. 
 
Cyclic adenosine mono phosphate (cAMP) is a major component of various pathways which    
regulate cell growth and proliferation among other functions. The pathway begins with a 
membrane bound receptor that usually binds an endocrine hormone. The receptor is bound to a 
transmembrane protein that, once activated, stimulates a stimulatory or inhibitory trimeric G-
protein, a guanine nucleotide-binding protein that acts as a switch inside cells to transmit signals 
that are received outside of the cell.  The G-protein stimulates adenylate cyclase to cause the 
cyclization of ATP to cAMP.  cAMP stimulates protein kinase A (PKA), which will convert ATP to 
AMP to phosphorylate other proteins.  PKA will also phosphorylate the transcription factor cAMP 
Responsive Element Binding Protein (CREB). Once CREB is phosphorylated, it is activated and 
diffuses inside the nucleus where it interacts with DNA as a transcription factor, causing the 
transcription of certain genes. 
 
8-Cl-cAMP and 8-Cl-Adenosine are both under clinical trials for their therapeutic effects in 
treating various types of cancer. These trials have met many issues, one of the major problems 
is their solubility properties. 8-Cl-cAMP is known to have high water solubility similar to that of 
vitamin C, thus the drug is not able to maintain high enough concentrations in the body to illicit a 
response before it is excreted. This problem was overcome by increasing the dosage given to 
patients which caused toxic side effects. These side effects can be mitigated, however, by what 
has been proposed here. Keeping in mind the solubility of 8-Cl-Adenosine and the fact that it is 
readily converted to 8-Cl-ATP which can be further converted to 8-Cl-cAMP through human 
biological pathways, a dosage of 8-Cl-Adenosine dissolved in human serum albumin could 
provide a constant 8-Cl-cAMP concentration in the blood serum for anti-cancer treatment. 
 
Lowering the dosage of 8-Cl-cAMP and adding an IV dosage of 8-Cl-Adenosine would not only 
provide patients with the enhanced anti-cancer effects but also give the body a less toxic source 
of 8-Cl-cAMP in the form of 8-Cl-Adenosine. While this modification requires additional clinical 
research, augmenting 8-Cl-cAMP treatment with 8-Cl-Adenosine can give patients the more 
clinical benefits with minimum toxicity. 
Patient Selection Criteria & Treatment 
 
 
• Diagnosis of lymphocytic leukemia 
• Rai Stage III or IV & 18 years or older 
• Zubrod performance status less than or equal to 2 
• Dosage of the Intravenous Treatment: 
 
o 8-Chloro-Adenosine = 45mg/m2/hr 
o 8-Chloro-cAMP = 0.15 mg/kg/hr 
oOne hour per treatment,  3 times/week for 4 weeks 
